BGG Relaunches ApplePhenon With Four Clinical Studies, Targets GLP-1 Users

BGG has four clinical studies backing ApplePhenon, its apple extract for weight management, and it relaunched the ingredient last year with a metabolic health focus. The company presented the research and a new beverage application at SupplySide Global 2026, where Nutritional Outlook's Nicholas Jacobus interviewed Lixin Ding, BGG's chief scientific officer.

The ingredient itself is not new. ApplePhenon has been studied for many years, Ding said, and its researched health benefits span cardiovascular health, skin health, respiratory function, immunity and anti-allergy effects. What is new is the positioning. The relaunch concentrates the message on metabolic outcomes, supported by studies Ding said address three specific areas: weight management, LDL cholesterol reduction and glucose reduction.

Why is BGG pointing the ingredient at GLP-1 users?

The positioning follows the boom in GLP-1 weight-loss drugs. Ding framed the strategy explicitly around what those drugs do not solve.

"I think this matches pretty well with current trend about GLP-1 campaign, because you know the weight loss, of course, that's a positive, but there's also other negative things of GLP-1 campaigns," Ding said. "For example, the loss of muscle and also the body composition change."

Ding said ApplePhenon can address several of the factors caused by GLP-1 use. He did not specify which of the four studies tested muscle preservation or body composition, and the interview offered no dosing data, trial size or duration for any of the four. Those gaps matter. Claims about muscle loss and body composition are the hardest to support without direct trial evidence, and none was presented here.

Why watermelon-tamarind-cayenne?

The flavor choice came from market research, not from the lab. Ding said BGG studied U.S. flavor trends to guide the formulation.

"We studied the market trend in the U.S. around what is the most popular flavor in the market, and we found that the watermelon and tamarind is on the top of the list," Ding said.

The format choice is also market-driven. Ding noted that while ApplePhenon supports many application types and dosage forms, the ready-to-drink, portable beverage is the growth segment. He cited three reasons: nutrition, clinically backed benefits and hydration.

What the story does not say

The interview leaves several questions open. BGG did not disclose the sample sizes, durations or endpoints of the four studies. The company did not name a launch customer, a price point or a timeline for the beverage concept reaching retail. Whether the extract's muscle-related claims will appear on labels depends on regulatory review, and Ding made no comment on that process.

The ingredient-supply side of the equation also went unaddressed. BGG did not discuss apple sourcing, extraction economics or how the relaunch pricing compares with competing polyphenol extracts.

For now, the concept stands as a formulation play aimed at the fastest-growing consumer segment in weight management. Whether the four studies carry the GLP-1-adjacent claims will depend on data BGG has not yet published in detail.